成纤维细胞在肝癌发生发展中的作用

doi:10.11904/j.issn.1002-3070.2022.02.012

摘要/Abstract

摘要： 肝脏发生纤维化及进一步产生的肝硬化是肝癌发生发展的重要因素。成纤维细胞可以使细胞外基质沉积,而细胞外基质沉积也是肝脏纤维化的标志性改变。成纤维细胞有多种来源,主要是由于肝损伤的性质不同。目前认为成纤维细胞主要来源于肝星状细胞(Hepatic stellate cells,HSCs),亦称为Ito细胞。在肝细胞癌(Hepatocellular carcinoma,HCC)的发生发展过程中肝成纤维细胞可以转化为肿瘤相关成纤维细胞(Cancer-associated fibroblasts,CAFs)。活化的肝星状细胞(Activated HSCs,AHSCs)/CAFs在HCC的发生发展中的作用已经被证实。CAFs是HCC中的肿瘤微环境(The tumor microenvironment,TME)中一组具有不同细胞来源和表型的活化成纤维细胞,与肿瘤的发生发展密切相关。CAFs可能通过分泌多种生长因子和细胞因子,促进细胞外基质重塑、增强肝癌细胞的干性、促进肿瘤耐药、促进肝癌的血管生成和血管生成拟态(Vasculogenic mimicry,Vm)来影响肿瘤细胞的增殖、凋亡、迁移、侵袭、血管生成、免疫逃逸和耐药性。由于存在上述特性,CAFs可以作为肿瘤治疗中的理想靶点。在这篇综述中,我们将对HCC中CAFs的最新认识、其细胞起源以及生物学功能进行阐释。

关键词: 癌症相关成纤维细胞, 肝细胞癌, 肿瘤微环境, 分子靶点

Abstract: Liver fibrosis and further cirrhosis are important factors in the occurrence and development of liver cancer.Fibroblasts can deposit extracellular matrix,and extracellular matrix deposition is also a hallmark of liver fibrosis.Liver fibrosis and further cirrhosis are important factors in the occurrence and development of liver cancer.There are many sources of fibroblasts,and the different sources are mainly due to the different nature of liver damage.It is currently believed that fibroblasts are mainly derived from hepatic stellate cells(Hepatic stellate cells,HSCs),also known as Ito cells.Liver fibroblasts can transform into cancer-associated fibroblasts(CAFs)during the occurrence and development of hepatocellular carcinoma(HCC).The role of activated hepatic stellate cells(activated HSCs,AHSCs)/tumor-associated fibroblasts(CAFs)in the occurrence and development of HCC has been confirmed.CAFs are a group of activated fibroblasts with different cell sources and phenotypes in the tumor microenvironment(TME)of HCC,and are closely related to the occurrence and development of tumors.CAFs may secrete a variety of growth factors and cytokines,promote extracellular matrix remodeling,enhance the stemness of liver cancer cells,promote tumor resistance,promote liver cancer angiogenesis and vasculogenic mimicry(Vm)to affect tumors cell proliferation,apoptosis,migration,invasion,angiogenesis,immune escape and drug resistance.Because of the above characteristics,CAFs can be used as ideal targets in tumor treatment.In this review,we will explain the latest understanding of HCC CAFs,their cell origin and biological functions.

Key words: Cancer-associated fibroblasts, Hepatocellular carcinoma, Tumor microenvironment, Molecular targets

中图分类号:

R730.22

刘雨, 俞星新, 耿志达, 陈政良, 惠鹏, 梁英健. 成纤维细胞在肝癌发生发展中的作用[J]. 实用肿瘤学杂志, 2022, 36(2): 167-172.

LIU Yu, YU Xingxin, GENG Zhida, CHEN Zhengliang, HUI Peng, LIANG Yingjian. The role of liver fibroblasts in the occurrence and development of hepatocellular carcinoma[J]. Journal of Practical Oncology, 2022, 36(2): 167-172.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2022.02.012

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2022/V36/I2/167

参考文献

1 Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
2 Azar SS,Mansoori M,Attar M,et al.Tumor necrosis factor alpha 308 G/A single nucleotide polymorphism and susceptibility to hepatocellular carcinoma via hepatitis B infection[J].Asian Pac J Cancer Prev,2016,17(7):3381-3384.
3 Medavaram S,Zhang Y.Emerging therapies in advanced hepatocellular carcinoma[J].Exp Hematol Oncol,2018,7:17.
4 Hernandez-Gea V,Friedman SL.Pathogenesis of liver fibrosis[J].Annu Rev Pathol,2011,6:425-456.
5 O′Rourke JM,Sagar VM,Shah T,et al.Carcinogenesis on the background of liver fibrosis:implications for the management of hepatocellular cancer[J].World J Gastroenterol,2018,24(39):4436-4447.
6 Jung YK,Yim HJ.Reversal of liver cirrhosis:current evidence and expectations[J].Korean J Intern Med,2017,32(2):213-228.
7 Buti M,Fung S,Gane E,et al.Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years[J].Hepatol Int,2015.9(2):243-250.
8 D′Ambrosio R,Aghemo A,Rumi MG,et al.A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis[J].Hepatology,2012,56(2):532-543.
9 Papatheodoridis GV,Chan HL,Hansen BE,et al.Risk of hepatocellular carcinoma in chronic hepatitis B:assessment and modification with current antiviral therapy[J].J Hepatol,2015,62(4):956-967.
10 Bang CS,Song IH.Impact of antiviral therapy on hepatocellular carcinoma and mortality in patients with chronic hepatitis C:systematic review and meta-analysis[J].BMC Gastroenterol,2017,17(1):46.
11 Kaplan DE.Immunopathogenesis of hepatitis c virus infection[J].Gastroenterol Clin North Am,2015,44(4):735-760.
12 Friedman SL.Mechanisms of hepatic fibrogenesis[J].Gastroenterology,2008,134(6):1655-1669.
13 Tsuchida T,Friedman SL.Mechanisms of hepatic stellate cell activation[J].Nat Rev Gastroenterol Hepatol,2017,14(7):397-411.
14 Affo S,Yu LX,Schwabe RF.The role of cancer-associated fibroblasts and fibrosis in liver cancer[J].Annu Rev Pathol,2017,12:153-186.
15 Kostallari E,Hirsova P,Prasnicka A,et al.Hepatic stellate cell-derived platelet-derived growth factor receptor-alpha-enriched extracellular vesicles promote liver fibrosis in mice through SHP2[J].Hepatology,2018,68(1):333-348.
16 Mederacke I,Hsu CC,Troeger JS,et al.Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology[J].Nat Commun,2013,4:2823.
17 Zhou Y,Ren H,Dai B,et al.Hepatocellular carcinoma-derived exosomal miRNA-21 contributes to tumor progression by converting hepatocyte stellate cells to cancer-associated fibroblasts[J].J Exp Clin Cancer Res,2018,37(1):324.
18 Zou B,Liu X,Gong Y,et al.A novel 12-marker panel of cancer-associated fibroblasts involved in progression of hepatocellular carcinoma[J].Cancer Manag Res,2018,10:5303-5311.
19 Sekiya S,Miura S,Matsuda-Ito K,et al.Myofibroblasts derived from hepatic progenitor cells create the tumor microenvironment[J].Stem Cell Reports,2016,7(6):1130-1139.
20 Pan T,Chen Y,Zhuang Y,et al.Synergistic modulation of signaling pathways to expand and maintain the bipotency of human hepatoblasts[J].Stem Cell Res Ther,2019,10(1):364.
21 Kollmorgen G,Palme K,Seidl A,et al.A re-engineered immunotoxin shows promising preclinical activity in ovarian cancer[J].Sci Rep,2017,7(1):18086.
22 Li Y,Wang J,Asahina K.Mesothelial cells give rise to hepatic stellate cells and myofibroblasts via mesothelial-mesenchymal transition in liver injury[J].Proc Natl Acad Sci U S A,2013,110(6):2324-2329.
23 Lua I,Asahina K.The role of mesothelial cells in liver development,injury,and regeneration[J].Gut Liver,2016,10(2):166-176.
24 Shafiq A,Suwakulsiri W,Rai A,et al.Transglutaminase-2,RNA-binding proteins and mitochondrial proteins selectively traffic to MDCK cell-derived microvesicles following H-Ras-induced epithelial-mesenchymal transition[J].Proteomics,2021,21(13/14):2000221.
25 Gu X,Huang D,Ci L,et al.Fate tracing of hepatocytes in mouse liver[J].Sci Rep,2017,7(1):16108.
26 Zeisberg M,Yang C,Martino M,et al.Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition[J].J Biol Chem,2007,282(32):23337-23347.
27 Scholten D,Osterreicher CH,Scholten A,et al.Genetic labeling does not detect epithelial-to-mesenchymal transition of cholangiocytes in liver fibrosis in mice[J].Gastroenterology,2010,139(3):987-998.
28 Taura K,Miura K,Iwaisako K,et al.Hepatocytes do not undergo epithelial-mesenchymal transition in liver fibrosis in mice[J].Hepatology,2010,51(3):1027-1036.
29 Xu J,Liu X,Koyama Y,et al.The types of hepatic myofibroblasts contributing to liver fibrosis of different etiologies[J].Front Pharmacol,2014,5:167.
30 Nunnari G,Vancheri C,Gilli E,et al.Circulating fibrocytes as a marker of liver fibrosis in chronic hepatitis C[J].Front Biosci(Elite Ed),2010,2:1241-1245.
31 Iwaisako K,Jiang C,Zhang M,et al.Origin of myofibroblasts in the fibrotic liver in mice[J].Proc Natl Acad Sci U S A,2014,111(32):3297-3305.
32 Nishio T,Hu R,Koyama Y,et al.Activated hepatic stellate cells and portal fibroblasts contribute to cholestatic liver fibrosis in MDR2 knockout mice[J].J Hepatol,2019,71(3):573-585.
33 Naba A,Clauser KR,Mani DR,et al.Quantitative proteomic profiling of the extracellular matrix of pancreatic islets during the angiogenic switch and insulinoma progression[J].Sci Rep,2017,7:40495.
34 Ghaly M,Gogineni E,Saif MW.The Evolving field of stereotactic body radiation therapy in pancreatic cancer[J].Pancreas(Fairfax),2019,3(1):9-14.
35 Santamato A,Fransvea E,Dituri F,et al.Hepatic stellate cells stimulate HCC cell migration via laminin-5 production[J].Clin Sci(Lond),2011,121(4):159-168.
36 Fiori ME,Di Franco S,Villanova L,et al.Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance[J].Mol Cancer,2019,18(1):70.
37 Pan X,Li M,Huang L,et al.CD44,IL-33,and ST2 gene polymorphisms on hepatocellular carcinoma susceptibility in the Chinese population[J].Biomed Res Int,2020,2020:2918517.
38 Zhang T,Huang Y,Liu W,et al.Overexpression of zinc finger protein 687 enhances tumorigenic capability and promotes recurrence of hepatocellular carcinoma[J].Oncogenesis,2017,6(7):e363.
39 Lau EY,Lo J,Cheng BY,et al.Cancer-associated fibroblasts regulate tumor-initiating cell plasticity in hepatocellular carcinoma through c-Met/FRA1/HEY1 signaling[J].Cell Rep,2016,15(6):1175-1189.
40 Li Y,Wang R,Xiong S,et al.Cancer-associated fibroblasts promote the stemness of CD24+ liver cells via paracrine signaling[J].J Mol Med(Berl),2019,97(2):243-255.
41 Xiong S,Wang R,Chen Q,et al.Cancer-associated fibroblasts promote stem cell-like properties of hepatocellular carcinoma cells through IL-6/STAT3/Notch signaling[J].Am J Cancer Res,2018,8(2):302-316.
42 Xu J,Wan Z,Tang M,et al.N6-methyladenosine-modified CircRNA-SORE sustains sorafenib resistance in hepatocellular carcinoma by regulating β-catenin signaling[J].Mol Cancer,2020,19(1):163.
43 Fang T,Lv H,Lv G,et al.Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer[J].Nat Commun,2018.9(1):191.
44 Peng H,Xue R,Ju Z,et al.Cancer-associated fibroblasts enhance the chemoresistance of CD73+ hepatocellular carcinoma cancer cells via HGF-Met-ERK1/2 pathway[J].Ann Transl Med,2020,8(14):856.
45 Liu J,Li P,Wang L,et al.Cancer-associated fibroblasts provide a stromal niche for liver cancer organoids that confers trophic effects and therapy resistance[J].Cell Mol Gastroenterol Hepatol,2021,11(2):407-431.
46 Bai C,Sun Y,Pan X,et al.Antitumor effects of trimethylellagic acid isolated from sanguisorba officinalis L.on colorectal cancer via angiogenesis inhibition and apoptosis induction[J].Front Pharmacol,2019,10:1646.
47 Hanahan D,Weinberg RA.Hallmarks of cancer:the next generation[J].Cell,2011,144(5):646-674.
48 Kubo N,Araki K,Kuwano H,et al.Cancer-associated fibroblasts in hepatocellular carcinoma[J].World J Gastroenterol,2016,22(30):6841-6850.
49 Xia Y,Cai XY,Fan JQ,et al.The role of sema4D in vasculogenic mimicry formation in non-small cell lung cancer and the underlying mechanisms[J].Int J Cancer,2019,144(9):2227-2238.
50 Louault K,Li RR,DeClerck YA.Cancer-associated fibroblasts:understanding their heterogeneity[J].Cancers(Basel),2020,12(11):3108.
51 Monteran L,Erez N.The dark side of fibroblasts:cancer-associated fibroblasts as mediators of immunosuppression in the tumor microenvironment[J].Front Immunol,2019,10:1835.
52 Law AM,Lim E,Ormandy CJ,et al.The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy[J].Endocr Relat Cancer,2017,24(4):123-144.
53 Li J,Sun J,Rong R,et al.HMGB1 promotes myeloid-derived suppressor cells and renal cell carcinoma immune escape[J].Oncotarget,2017,8(38):63290-63298.
54 Cheng JT,Deng YN,Yi HM,et al.Hepatic carcinoma-associated fibroblasts induce IDO-producing regulatory dendritic cells through IL-6-mediated STAT3 activation[J].Oncogenesis,2016,5:e198.
55 Koppe C,Reisinger F,Wehr K,et al.An NF-kappaB-and IKK-Independent function of NEMO prevents hepatocarcinogenesis by suppressing compensatory liver regeneration[J].Cancers(Basel),2019,11(7):999.

[1]	王宗文, 李小东, 朱乾坤, 曾世聪, 翟博. KIF14在肝细胞癌SMCC-7721获得性耐药机制中的研究[J]. 实用肿瘤学杂志, 2022, 36(1): 14-19.
[2]	董丽娜, 梁田, 张献, 张广美. 卵巢癌对富脂大网膜的器官趋向性转移的研究进展[J]. 实用肿瘤学杂志, 2022, 36(1): 54-58.
[3]	牟冠男, 马强. NK细胞极化在子宫内膜癌中的作用[J]. 实用肿瘤学杂志, 2021, 35(6): 534-537.
[4]	刘菲, 隋红. 基于肿瘤免疫微环境的肝癌分子分型研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 557-561.
[5]	纪雷, 纪道林, 鲍冬冬, 谭刚. lncRNA在肝细胞癌索拉非尼耐药中的最新研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 562-567.
[6]	赵浩然, 李满, 张玉宝. 肝细胞癌相关RNA结合蛋白研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 576-579.
[7]	隆园辉, 陈雪松. 心理应激对肿瘤微环境中免疫细胞影响的研究进展[J]. 实用肿瘤学杂志, 2021, 35(5): 436-440.
[8]	贺玲, 姚克铖. 糖基磷脂酰肌醇转酰胺酶与肝癌[J]. 实用肿瘤学杂志, 2021, 35(5): 458-461.
[9]	张慧婷, 娄阁. 卵巢癌肿瘤微环境的三维细胞培养模型研究进展[J]. 实用肿瘤学杂志, 2019, 33(6): 557-560.
[10]	曲雁飞, 刘超, 王勃军, 方琳, 张艳桥. CSN6基因在肝细胞癌组织中的表达及临床意义[J]. 实用肿瘤学杂志, 2019, 33(4): 328-333.
[11]	李悦, 徐可, 韩增祥, 孙敏, 樊国华综述, 张勇审校. 结肠癌中肿瘤相关巨噬细胞的作用及靶向治疗的研究进展[J]. 实用肿瘤学杂志, 2018, 32(5): 450-454.
[12]	吕强, 陈洪生, 李国东, 魏九峰(综述), 刘明(审校). 肿瘤相关成纤维细胞在大肠癌发生发展中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(3): 275-279.
[13]	张培, 曹守波, 于雁. 自噬介导的肿瘤相关巨噬细胞调控机制的研究进展[J]. 实用肿瘤学杂志, 2018, 32(2): 130-134.
[14]	雷婉婷, 王静萱. 肿瘤微环境在肿瘤细胞有氧糖酵解中的作用[J]. 实用肿瘤学杂志, 2018, 32(2): 189-192.
[15]	申美莹, 庞达. 长链非编码RNA在肿瘤微环境中的调控作用[J]. 实用肿瘤学杂志, 2018, 32(1): 73-76.